CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) indication: for the treatment of adult patients with moderately to severely active Crohn disease
The CADTH Canadian Drug Expert Committee (CDEC) recommends that vedolizumab subcutaneous (SC) be reimbursed for the treatment of adult patients with moderately to severely active Crohn disease, only if certain conditions are met
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
January 2021, 2021
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that vedolizumab subcutaneous (SC) be reimbursed for the treatment of adult patients with moderately to severely active Crohn disease, only if certain conditions are met |
|---|---|
| Physical Description: | 1 PDF file (8 pages) |